Skip to content
  1. Home/
  2. Latest news/
  3. Chairman and CEO Alex Gorsky profiled by the Financial Times about Johnson & Johnson’s work on a potential COVID-19 vaccine
lede-alex-gorsky-financial-time-3.jpg

Chairman and CEO Alex Gorsky profiled by the Financial Times about Johnson & Johnson’s work on a potential COVID-19 vaccine

The article explores what guided the decision, which is just the latest example of our Chairman and CEO’s people-first approach to leadership at our healthcare company.

Johnson & Johnson scientists are fast at work on a potential vaccine for COVID-19 that our company plans to provide on a not-for-profit basis.

It’s a decision that underscores our company’s deep commitment to its 77-year-old mission statement, known as Our Credo, which states that Johnson & Johnson’s “first responsibility is to the patients, doctors and nurses, to mothers and fathers and all others who use our products and services. In meeting their needs everything we do must be of high quality.”

That commitment permeates the decisions that Gorsky makes both inside and outside our company, especially during this coronavirus pandemic.

In this Financial Times profile, read about the decision to make the vaccine available on a not-for-profit basis, his work to help redefine the purpose of corporations through the U.S. Business Roundtable—and his people-first approach to leading at Johnson & Johnson.

Read the article: Johnson & Johnson Chief Looks to the Greater Good

How Johnson & Johnson Is Responding to the COVID-19 Pandemic

Learn about the innovative ways the company is mobilizing to help combat the global outbreak caused by the novel coronavirus.

More from Johnson & Johnson

Johnson & Johnson named to Fortune’s 2025 America’s Most Innovative Companies list

The company’s commitment to developing solutions that tackle the world’s most pressing health challenges has helped Johnson & Johnson be recognized as the top-ranked healthcare company on the list.

Inside Johnson & Johnson’s decades-long quest to develop effective treatments for IBD

Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.

The future of immunology

Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.